Heart failure & cardiomyopathiesCohort study
Clinical and Plasma Proteomic Characterization of Heart Failure with Supranormal Left Ventricular Ejection Fraction: An Emerging Entity of heart failure
- Cohort study
Authors' conclusion
Heart failure with supranormal ejection fraction, an unnoticed but emerging entity in HF, carries a similarly increased cardiovascular risk as HFrEF but has unique structural and plasma proteomic characteristics.
Study context
- Population
- Patients with heart failure (HF) from the CHART-Omics study; Left ventricular ejection fraction (LVEF) cutoffs 35%, 55%, 70% (men) and 40%, 60%, 75% (women)CHART-Omics
- Participants
- 442 patients
- Exposure
- HF categories by LVEF cutoffs, HF with supranormal ejection fraction (HFsnEF) vs HF with normal ejection fraction (HFnEF)
- HF with reduced ejection fraction (HFrEF)n = 55
- HF with mildly reduced ejection fraction (HFmrEF)n = 125
- HFnEFn = 215reference
- HFsnEFn = 47
- Outcome
- Composite of:
- CV death
- HF hospitalization
Main finding
As reported in the abstract
Each group vs HFnEFHazard ratio (95% CI)P value
HFsnEF
2.71(1.10–6.66)
P = 0.030HFrEF
3.14(1.36–7.23)
P = 0.007Observational data: associations, not effects.
Further findings
LV structure
- HFsnEF: increased relative LV wall thickness, decreased LV dimensions; HFrEF: increased LV mass and dimensions
Plasma proteomics (4670 proteins)
- Essential differences between HFsnEF and HFrEF in pathophysiology and prognostication pathways
Original publication
Clinical and Plasma Proteomic Characterization of Heart Failure with Supranormal Left Ventricular Ejection Fraction: An Emerging Entity of heart failure. Eur J Heart Fail. Published 15 April 2025. doi:10.1002/ejhf.3654
Summarised from the published abstract; every number is checked against it